Cover Image
Market Research Report

Sciatica - Market Insights, Epidemiology and Market Forecast - 2028

Published by DelveInsight Business Research LLP Product code 915405
Published Content info 139 Pages
Delivery time: 1-2 business days
Price
Back to Top
Sciatica - Market Insights, Epidemiology and Market Forecast - 2028
Published: November 1, 2019 Content info: 139 Pages
Description

DelveInsight's 'Sciatica-Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sciatica in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sciatica from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Sciatica - Disease Understanding and Treatment Algorithm

Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low-back and extends through the buttock area to send nerve endings down the lower limb. Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. In maximum cases it is caused by a herniated disc with nerve root compression, but lumbar stenosis and tumors are other possible causes.

Sciatica is mainly diagnosed by history taking and physical examination. Physical examination largely depends on neurological testing. The most applied investigation is the straight leg raising test or Lasegue's sign. Diagnostic imaging is only useful if the results affect further management. Diagnostic imaging is only useful if the results affect further management. The neurological exam often is performed to measure muscle strength, reflexes, and nerve impulses. Some useful tests are X-ray, Magnetic resonance imaging (MRI scan), CT scan, Electromyography, Bone scan, Electromyogram, and others. In patients with subacute or chronic radicular symptoms, there is evidence that a single TFESI has similar efficacy as a single transforaminal injection of bupivacaine or saline. It is used in the treatment of lumbosacral radicular pain. The diagnosis requires careful interpretation of examination results in context with the patient's clinical appearance as well as the exclusion of a broad variety of differential diagnoses.

The DelveInsight Sciatica market report gives the thorough understanding of Sciatica by including details such as disease introduction, symptoms, pathophysiology and mechanism, biomarkers, diagnosis and differential diagnosis.

Sciatica Epidemiology

According to the Centers for Disease Control and Prevention (CDC), pain is a leading cause of disability and a major contributor to health care utilization. It is often associated with a wide range of injury and disease. Worldwide, the ages lived with disability caused by low-back pain have increased by 54% between 1990 and 2015.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Sciatica in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

The disease epidemiology covered in the report is segmented by:

  • Diagnosed Prevalence of Sciatica
  • Lumbar Disc Herniation Cases
  • Gender-specific Diagnosed Prevalence of Sciatica
  • Age-specific Diagnosed Prevalence

Vahdatinia et al. conducted a study titled "Treatment Options for Sciatica: Surgery, Epidural Injections, and Osteopathic Manipulative Treatment" that compared patients suffering from sciatica for 6-12 weeks who underwent early microdiscectomy (approximately 2 weeks) versus those who followed prolonged conservative treatment. The patients undergoing early surgery reported faster relief of leg pain at 3 months and had a median recovery time of 4 weeks and up to 1-2 years follow-up, there were no differences between the two groups. Another study in the same follows up for both the conservative group and surgery group improved with regards to primary (leg and/or back pain, perceived recovery, leg pain-specific functional status) and secondary outcomes with no statistically significant differences. On average, 80% of patients were able to avoid surgical intervention with the help of epidural injection treatment.

A German study conducted by Henschke et al. titled "The Epidemiology and Economic Consequences of Pain" stated that in children and adolescents, the cases reported were of 1 year incidence of low-back pain ranging from 11.8% to 33.0%, with the 1 month prevalence ranging from 9.8% to 36.0%. In addition to this, a survey published showed that over 400,000 children and adolescents aged 11-15 years reported the 1 month prevalence of low-back pain to be 37%. The incidence of sciatica over 1 year was reported to be 9.3% and the 1 month prevalence of sciatica ranges from 0.4% to 16.4%.

Sciatica Drug Chapters

This segment of the Sciatica report encloses the detailed analysis of pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Sciatica and awareness of the disease. The overall dynamics of Sciatica market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Semnur Pharmaceuticals and Seikagaku Corporation will significantly increase the market during the forecast period (2019-2028).

Sciatica Market Outlook

Sciatica is characterized by radiating posterior or posterolateral leg pain, which is sometimes accompanied by back pain, sensory loss, weakness, or reflex abnormalities. The nerve branches from the spine to the left and right buttocks and then travel down the back of the legs, at about the middle of the thighs, to the feet. Sciatica pain greatly affects the quality of life of the people since it is difficult to know and diagnose the root cause.

The treatment for sciatica majorly includes nonsurgical and surgical protocols, wherein, nonsurgical protocol includes physical therapy and medications. Bed rest has been traditionally supported for the treatment of acute sciatica. While the surgical protocol is the last option to be followed as patients do not get relief from nonsurgical interventions. First-line treatments of sciatica typically include some combination of physical therapy, medications, therapeutic injections, and alternative therapies. A wide array of passive options are available such as deep tissue massage, hot and cold therapies, transcutaneous electrical nerve stimulation, ultrasound, hydrotherapy. Cognitive behavior therapy (CBT) is a form of psychotherapy that explores and improves the connection between thoughts, emotions, and behaviors. The commonly followed interventions to treat sciatica include pain relievers, muscle relaxants, anti-inflammatories, antidepressants, calcium channel α2-δ ligands, epidural steroids, opioids, and topical pain medications.

This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Sciatica in 7MM is expected to change from 2019-2028.

Sciatica Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for sciatica such as SP-102 (Semnur Pharmaceutical) and Condoliase (Seikagaku Corporation) in the forecast period [2019-2028] will also create a positive impact on the sciatica market.

Sciatica Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sciatica Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Sciatica Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Sciatica market
  • Organize sales and marketing efforts by identifying the best opportunities for Sciatica market
  • To understand the future market competition in the Sciatica market.
Table of Contents
Product Code: DIMI0572

Table of Contents

1. Key Insights

2. Sciatica Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Sciatica in 2017
  • 2.2. Market Share (%) Distribution of Sciatica in 2028

3. Disease Background and Overview: Sciatica

  • 3.1. Introduction
  • 3.2. Difference between Sciatica and Lower Back Pain
  • 3.3. Symptoms of Sciatica
  • 3.4. Causes of Sciatica
    • 3.4.1 Spinal Disc Herniation
    • 3.4.2 Spinal Stenosis
    • 3.4.3 Pregnancy
    • 3.4.4 Piriformis syndrome
    • 3.4.5 Osteoarthritis
    • 3.4.6 Spondylosis and spondylolisthesis
    • 3.4.7 Nondiscogenic causes
  • 3.5. Pathophysiology of disk-related sciatica
    • 3.5.1 Clinical observation
    • 3.5.2 Physiologic Variants of Sciatica
  • 3.6. Pathophysiological Mechanisms in Radicular Pain
    • 3.6.1 Inflammatory mechanism
    • 3.6.2 Immunological mechanism
    • 3.6.3 Compressive mechanism
    • 3.6.4 Lumbar spinal stenosis
    • 3.6.5 Skeletal Causes of Radiculopathy
    • 3.6.6 Lumbar bulging or herniated disc
  • 3.7. Biomarkers for Sciatica
  • 3.8. Diagnosis of sciatica
    • 3.8.1 Indicators for sciatica
    • 3.8.2 Imaging
    • 3.8.3 Selective Nerve Root Block (SRNB)
  • 3.9. Differential Diagnosis
  • 3.10. Clinical Guidelines for the Diagnosis for Sciatica
    • 3.10.1 Clinical guideline for diagnosis for General Practice
  • 3.11. Diagnostic algorithm

4. Epidemiology and Patient Population: Key Findings

  • 4.1 7MM Total Diagnosed Prevalent Patient Population of Sciatica

5. Country Wise-Epidemiology of Sciatica

  • 5.1 United States
    • 5.1.1 Assumptions and Rationale
    • 5.1.2 Sciatica Diagnosed Prevalence in the United States
    • 5.1.3 Lumbar Disc Herniation Cases in the United States
    • 5.1.4 Sciatica Gender-specific Diagnosed Prevalence in the United States
    • 5.1.5 Sciatica Age-specific Diagnosed Prevalence in the United States
  • 5.2 EU5 Countries
    • 5.2.1 Assumptions and Rationale
  • 5.3 Germany
    • 5.3.1 Sciatica Diagnosed Prevalence in Germany
    • 5.3.2 Lumbar Disc Herniation Cases in Germany
    • 5.3.3 Sciatica Gender-specific Diagnosed Prevalence in Germany
    • 5.3.4 Sciatica Age-specific Diagnosed Prevalence in Germany
  • 5.4 France
    • 5.4.1 Sciatica Diagnosed Prevalence in France
    • 5.4.2 Lumbar Disc Herniation Cases in France
    • 5.4.3 Sciatica Gender-specific Diagnosed Prevalence in France
    • 5.4.4 Sciatica Age-specific Diagnosed Prevalence in France
  • 5.5 Italy
    • 5.5.1 Sciatica Diagnosed Prevalence in Italy
    • 5.5.2 Lumbar Disc Herniation Cases in Italy
    • 5.5.3 Sciatica Gender-specific Diagnosed Prevalence in Italy
    • 5.5.4 Sciatica Age-specific Diagnosed Prevalence in Italy
  • 5.6 Spain
    • 5.6.1 Sciatica Diagnosed Prevalence in Spain
    • 5.6.2 Lumbar Disc Herniation Cases of Sciatica in Spain
    • 5.6.3 Sciatica Gender-specific Diagnosed Prevalence in Spain
    • 5.6.4 Sciatica Age-specific Diagnosed Prevalence in Spain
  • 5.7 United Kingdom
    • 5.7.1 Sciatica Diagnosed Prevalence in the United Kingdom
    • 5.7.2 Lumbar Disc Herniation Cases in the United Kingdom
    • 5.7.3 Sciatica Gender-specific Diagnosed Prevalence in the United Kingdom
    • 5.7.4 Sciatica Age-specific Diagnosed Prevalence in the United Kingdom
  • 5.8 Japan
    • 5.8.1 Assumptions and Rationale
    • 5.8.2 Sciatica Diagnosed Prevalence in Japan
    • 5.8.3 Lumbar Disc Herniation Cases in Japan
    • 5.8.4 Sciatica Gender-specific Diagnosed Prevalence in Japan
    • 5.8.5 Sciatica Age-specific Diagnosed Prevalence in Japan

6 Treatment

  • 6.1 Nonsurgical Treatment for Sciatica
    • 6.1.1 Physical therapy
    • 6.1.2 Psychological therapies
    • 6.1.3 Medications
  • 6.2 Surgical Treatment of Sciatica

7 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain

  • 7.1 Grading the Evidence and Developing Recommendations
  • 7.2 Comparative Benefits of Pharmacologic Therapies
  • 7.3 Comparative Benefits of Nonpharmacologic Therapies
  • 7.4 Recommendations

8 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines

9 Unmet Needs

10 Emerging Drugs

  • 10.1 Key Cross Competition
  • 10.2 SP-102 (Semdexa): Semnur Pharmaceuticals/Scilex Holding Company
    • 10.2.1 Product Description
    • 10.2.2 Other Developmental Activities
    • 10.2.3 Clinical Development
    • 10.2.4 Product Profile
  • 10.3 SI-6603 (Condoliase): Seikagaku Corporation
    • 10.3.1 Product Description
    • 10.3.2 Other Developmental Activities
    • 10.3.3 Clinical Development
    • 10.3.4 Product Profile

11 Sciatica: 7 Major Market Analysis

  • 11.1 Key Findings
  • 11.2 Market Size of Sciatica in 7MM

12 The United States Market Outlook

  • 12.1 United States Market Size
    • 12.1.1 Total Market size of Sciatica
    • 12.1.2 Market Size by Therapies

13 EU-5 Countries: Market Outlook

  • 13.1 Germany
    • 13.1.1 Total Market size of Sciatica in Germany
    • 13.1.2 Market Size by Therapies
  • 13.2 France
    • 13.2.1 Total Market Size of Sciatica
    • 13.2.2 Market Size by Therapies
  • 13.3 Italy
    • 13.3.1 Total Market Size of Sciatica
    • 13.3.2 Market Size by Therapies
  • 13.4 Spain
    • 13.4.1 Total Market Size of Sciatica
    • 13.4.2 Market Size by Therapies
  • 13.5 United Kingdom
    • 13.5.1 Total Market Size of Sciatica
    • 13.5.2 Market Size by Therapies

14 Japan: Market Outlook

  • 14.1 Japan market Size
    • 14.1.1 Total Market Size of Sciatica
    • 14.1.2 Market Size by Therapies

15 Market Drivers

16 Market Barriers

17 Appendix

  • 17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

  • Table 1: Nondiscogenic causes of sciatica
  • Table 2: Physiologic Variants of Sciatica
  • Table 3: Total Diagnosed Population of Sciatica in the 7MM (2017-2028)
  • Table 4: Sciatica Diagnosed Prevalence in the United States (2017-2028)
  • Table 5: Lumbar Disc Herniation in the United States (2017-2028)
  • Table 6: Sciatica Gender-specific Diagnosed Prevalence in the United States (2017-2028)
  • Table 7: Sciatica Age-specific Diagnosed Prevalence in the United States (2017-2028)
  • Table 8: Sciatica Diagnosed Prevalence in Germany (2017-2028)
  • Table 9: Lumbar Disc Herniation in Germany (2017-2028)
  • Table 10: Sciatica Gender-specific Diagnosed Prevalence in Germany (2017-2028)
  • Table 11: Sciatica Age-specific Diagnosed Prevalence in Germany (2017-2028)
  • Table 12: Sciatica Diagnosed Prevalence in France (2017-2028)
  • Table 13: Lumbar Disc Herniation Cases in France (2017-2028)
  • Table 14: Sciatica Gender-specific Diagnosed Prevalence in France (2017-2028)
  • Table 15: Sciatica Age-specific Diagnosed Prevalence in France (2017-2028)
  • Table 16: Sciatica Diagnosed Prevalence in Italy (2017-2028)
  • Table 17: Lumbar Disc Herniation in Italy (2017-2028)
  • Table 18: Sciatica Gender-specific Diagnosed Prevalence in Italy (2017-2028)
  • Table 19: Sciatica Age-specific Diagnosed Prevalence in Italy (2017-2028)
  • Table 20: Sciatica Diagnosed Prevalence in Spain (2017-2028)
  • Table 21: Lumbar Disc Herniation in Spain (2017-2028)
  • Table 22: Sciatica Gender-specific Diagnosed Prevalence in Spain (2017-2028)
  • Table 23: Sciatica Age-specific Diagnosed Prevalence in Spain (2017-2028)
  • Table 24: Sciatica Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Table 25: Lumbar Disc Herniation in the United Kingdom (2017-2028)
  • Table 26: Sciatica Gender-specific Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Table 27: Sciatica Age-specific Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Table 28: Sciatica Diagnosed Prevalence in Japan (2017-2028)
  • Table 29: Lumbar Disc Herniation in Japan (2017-2028)
  • Table 30: Sciatica Gender-specific Diagnosed Prevalence in Japan (2017-2028)
  • Table 31: Sciatica Age-specific Diagnosed Prevalence in Japan (2017-2028)
  • Table 32: Comparison of Emerging Drugs Under Development
  • Table 33: SP-102, Clinical Trial Description
  • Table 34: SI-6603, Clinical Trial Description
  • Table 35: 7 Major Market Size of Sciatica in USD Million (2017-2028)
  • Table 36: United States Market Size of Sciatica , USD Million (2017-2028)
  • Table 37: Market size of Sciatica by therapies in the United States, in USD Million (2017-2028)
  • Table 38: Market Size of Sciatica in Germany, in USD Million (2017-2028)
  • Table 39: Market size of Sciatica by therapies in Germany, in USD Million (2017-2028)
  • Table 40: Market Size of Sciatica in France, in USD Million (2017-2028)
  • Table 41: Market size of Sciatica by therapies in France, in USD Million (2017-2028)
  • Table 42: Market Size of Sciatica in Italy, in USD Million (2017-2028)
  • Table 43: Market size of Sciatica by therapies in Italy, in USD Million (2017-2028)
  • Table 44: Market Size of Sciatica in Spain, in USD Million (2017-2028)
  • Table 45: Market size of Sciatica by therapies in Spain, in USD Million (2017-2028)
  • Table 46: Market Size of Sciatica in the UK, in USD Million (2017-2028)
  • Table 47: Market size of Sciatica by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 48: Market Size of Sciatica in Japan, in USD Million (2017-2028)
  • Table 49: Market size of Sciatica by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Types of lumbar disc herniation classification based on the location of the disc herniation relative to the facet joint and spinal canal.
  • Figure 2: Piriformis Muscles Syndrome
  • Figure 3: Pathophysiological mechanisms in radicular pain.
  • Figure 4: Pathoanatomical Features of Degenerative Lumbar Spinal Stenosis.
  • Figure 5: Algorithm for the diagnostic evaluation of patients with low-back pain.
  • Figure 6: Total Diagnosed Patient Population of Sciatica in the 7MM (2017-2028)
  • Figure 7: Sciatica Diagnosed Prevalence in the United States (2017-2028)
  • Figure 8: Lumbar Disc Herniation Cases in the United States (2017-2028)
  • Figure 9: Sciatica Gender-specific Diagnosed Prevalence in the United States (2017-2028)
  • Figure 10: Sciatica Age-specific Diagnosed Prevalence in the United States (2017-2028)
  • Figure 11: Sciatica Diagnosed Prevalence in Germany (2017-2028)
  • Figure 12: Lumbar Disc Herniation Cases of Sciatica in Germany (2017-2028)
  • Figure 13: Sciatica Gender-specific Diagnosed Prevalence in Germany (2017-2028)
  • Figure 14: Sciatica Age-specific Diagnosed Prevalence in Germany (2017-2028)
  • Figure 15: Sciatica Diagnosed Prevalence in France (2017-2028)
  • Figure 16: Lumbar Disc Herniation in France (2017-2028)
  • Figure 17: Sciatica Gender-specific Diagnosed Prevalence in France (2017-2028)
  • Figure 18: Sciatica Age-specific Diagnosed Prevalence in France (2017-2028)
  • Figure 19: Diagnosed Prevalence of Sciatica in Italy (2017-2028)
  • Figure 20: Lumbar Disc Herniation in Italy (2017-2028)
  • Figure 21: Sciatica Gender-specific Diagnosed Prevalence in Italy (2017-2028)
  • Figure 22: Sciatica Age-specific Diagnosed Prevalence in Italy (2017-2028)
  • Figure 23: Sciatica Diagnosed Prevalence in Spain (2017-2028)
  • Figure 24: Lumbar Disc Herniation in Spain (2017-2028)
  • Figure 25: Sciatica Gender- specific Diagnosed Prevalence in Spain (2017-2028)
  • Figure 26: Sciatica Age-specific Diagnosed Prevalence in Spain (2017-2028)
  • Figure 27: Sciatica Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Figure 28: Lumbar Disc Herniation in the United Kingdom (2017-2028)
  • Figure 29: Sciatica Gender-specific Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Figure 30: Sciatica Age-specific Diagnosed Prevalence in the United Kingdom (2017-2028)
  • Figure 31: Sciatica Diagnosed Prevalence in Japan (2017-2028)
  • Figure 32: Lumbar Disc Herniation in Japan (2017-2028)
  • Figure 33: Sciatica Gender-specific Diagnosed Prevalence in Japan (2017-2028)
  • Figure 34: Sciatica Age-specific Diagnosed Prevalence in Japan (2017-2028)
  • Figure 35: Treatment algorithm of Sciatica
  • Figure 36: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Figure 37: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Figure 38: Unmet Needs of Sciatica
  • Figure 39: 7 Major Market Size of Sciatica in USD Million (2017-2028)
  • Figure 40: Market Size of Sciatica in the United States, USD Millions (2017-2028)
  • Figure 41: Market size of Sciatica by therapies in the US, in USD Million (2017-2028)
  • Figure 42: Market Size of Sciatica in Germany, USD Million (2017-2028)
  • Figure 43: Market size of Sciatica by therapies in Germany, in USD Million (2017-2028)
  • Figure 44: Market Size of Sciatica in France, USD Million (2017-2028)
  • Figure 45: Market size of Sciatica by therapies in France, in USD Million (2017-2028)
  • Figure 46: Market Size of Sciatica in Italy, USD Million (2017-2028)
  • Figure 47: Market Size of Sciatica by therapies in Italy, in USD Million (2017-2028)
  • Figure 48: Market Size of Sciatica in Spain, USD Million (2017-2028)
  • Figure 49: Market Size of Sciatica by therapies in Spain, in USD Million (2017-2028)
  • Figure 50: Market Size of Sciatica in the UK, USD Million (2017-2028)
  • Figure 51: Market Size of Sciatica by therapies in the UK, in USD Million (2017-2028)
  • Figure 52: Market Size of Sciatica in Japan, USD Million (2017-2028)
  • Figure 53: Market size of Sciatica by therapies in Japan, in USD Million (2017-2028)
  • Figure 54: Market Drivers
  • Figure 55: Market Barriers
Back to Top